NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Suven Life Sciences Limited (NSE: SUVEN)

 
SUVEN Technical Analysis
4
As on 7th Dec 2021 SUVEN Share Price closed @ 89.65 and we RECOMMEND Sell for LONG-TERM with Stoploss of 90.04 & Strong Sell for SHORT-TERM with Stoploss of 99.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SUVEN Share Price

Open 89.20 Change Price %
High 91.40 1 Day -0.10 -0.11
Low 89.20 1 Week 1.35 1.53
Close 89.65 1 Month -14.20 -13.67
Volume 170290 1 Year 26.85 42.75
52 Week High 124.45 | 52 Week Low 63.15
 
NSE INDIA Most Active Stocks
IDEA 14.25 -5.00%
YESBANK 13.10 3.97%
NATIONALUM 96.60 7.10%
IFCI 15.40 3.36%
SAIL 107.75 4.71%
ZOMATO 139.80 0.90%
HFCL 77.85 %
TATAPOWER 226.45 2.54%
IBULHSGFIN 246.90 1.29%
HCC 13.00 0.39%
 
NSE INDIA Top Gainers Stocks
ARENTERP 41.70 20.00%
HITECHCORP 279.65 20.00%
MODISNME 99.80 19.95%
MOTOGENFIN 30.15 19.88%
LOVABLE 183.60 19.80%
ANSALHSG 8.60 19.44%
CTE 65.10 17.72%
CTE 65.10 17.72%
CTE 65.10 17.72%
CTE 65.10 17.72%
 
NSE INDIA Top Losers Stocks
PRIVISCL 1779.65 -6.85%
AAVAS 2485.10 -6.06%
RESPONIND 114.55 -5.53%
DPSCLTD 23.20 -5.31%
NXTDIGITAL 422.45 -5.12%
IDEA 14.25 -5.00%
IDEA 14.25 -5.00%
IDEA 14.25 -5.00%
PANACEABIO 201.45 -5.00%
JITFINFRA 131.50 -4.99%
 
 
SUVEN
Daily Charts
SUVEN
Intraday Charts
Whats New @
Bazaartrend
SUVEN
Free Analysis
 
SUVEN Important Levels Intraday
RESISTANCE93.89
RESISTANCE92.53
RESISTANCE91.69
RESISTANCE90.85
SUPPORT88.45
SUPPORT87.61
SUPPORT86.77
SUPPORT85.41
 
SUVEN Target for Month December
4th UP TARGET129.35
3rd UP TARGET116.18
2nd UP TARGET108.05
1st UP TARGET99.91
1st DOWN TARGET76.69
2nd DOWN TARGET68.55
3rd DOWN TARGET60.42
4th DOWN TARGET47.25
 
SUVEN Weekly Target
4th UP TARGET102.79
3rd UP TARGET98.90
2nd UP TARGET96.49
1st UP TARGET94.08
1st DOWN TARGET87.22
2nd DOWN TARGET84.81
3rd DOWN TARGET82.40
4th DOWN TARGET78.51
 
SUVEN Target for Year 2021
4th UP TARGET681.75
3rd UP TARGET492.15
2nd UP TARGET374.95
1st UP TARGET257.76
1st DOWN TARGET-76.66
2nd DOWN TARGET-193.85
3rd DOWN TARGET-311.05
4th DOWN TARGET-500.65
 
 
SUVEN Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is Below 20 Over Sold
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 151.94
10 Day Avg Volume Traded -70.15 % Less then 10 Day Average Volume
 
SUVEN Other Details
Segment EQ
Market Capital 12823661568.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
SUVEN Address
SUVEN
 
SUVEN Latest News
 
Your Comments and Response on Suven Life Sciences Limited
 
SUVEN Business Profile
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company's product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. It is also develops SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited. Address: # 8-2-334, SDE Serene Chambers, Hyderabad, India, 500034
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service